{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"15","upperLimit":"39","value":"26"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"}],"units":"Participants"}],"description":"Progression-free survival (PFS) is defined as the interval between day of transplant and day of death or disease progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Busulfan starting dose of 32 mg/m\\^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3. Fludarabine dose of 40 mg/m\\^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan. Cyclophosphamide dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.","id":"OG000","title":"Busulfan + Fludarabine + Cyclophosphamide"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"First 25-35 days post transplant and then every 3 months for a maximum of 2 years","title":"2-year Progression-Free Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}